Royalty Obligation and Deferred License Fees (Details)	12 Months Ended
	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 ILS (₪)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years	10 years
Amortization of deferred license, royalty and subscription revenues	$ 102,000		$ (1,000)	$ (915,000)
Amortization of deferred license fees [Abstract]
2016	148,000
2017	130,000
2018	84,000
2019	34,000
2020	13,000
Thereafter	61,000
Total	470,000
Prepaid expenses in other current assets	148,000
Deferred license fees in noncurrent assts	322,000		337,000
WARF [Member]
Finite-Lived Intangible Assets [Line Items]
Licensing fees paid	295,000
Amortization of deferred license, royalty and subscription revenues	$ 210,100		151,000
WARF [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	2.00%	2.00%
WARF [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	4.00%	4.00%
Ocata Therapeutics, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years	20 years
Royalty rate on sale of products and services	8.00%	8.00%
Licensing fees paid	$ 250,000
Amortization of deferred license, royalty and subscription revenues	209,900		$ 184,900
Maximum royalty payments	$ 1,000,000
Hadasit [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	5.00%	5.00%
Payment for patent expense	$ 63,900	₪ 249,100
Minimum percentage for underlying net sales	1.20%	1.20%
Annual minimum royalty due	$ 100,000
Minimum amount of sublicensing receipts	$ 50,000,000
Hadasit [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense	10.00%	10.00%
Hadasit [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense	30.00%	30.00%
Hadasit (Clinical trial phase I) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 250,000
Hadasit (Clinical trial phase II) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	250,000
Hadasit (Clinical trial phase III) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 1,000,000
University of Utah License [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	3.00%	3.00%
Fees for sublicense	30.00%	30.00%
Payments for attaining milestone	$ 5,000
Number of licensed patents issued that trigger payments to licensor | shares	5
Minimum royalty amount in 2015	$ 2,500
Minimum royalty amount in 2016 and thereafter	30,000
University of Utah License [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 2,500
Number of other licensees that triggers reduction in payments for attaining milestone | shares	2
University of Utah License, Milestone I [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 225,000
Asterias License from the University of California [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	1.00%	1.00%
Fees for sublicense	7.50%	7.50%
Annual minimum royalty due	$ 5,000
Maximum reduction in royalty payments	50.00%
Period of notice for termination of the agreement	60 days	60 days
Asterias Sublicenes from Geron [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	1.00%	1.00%
Licensing fees paid	$ 65,000
Period of notice for termination of the agreement	90 days	90 days
Annual license maintenance fee	$ 10,000
OrthoCyte Agreements with Heraeus [Member]
Finite-Lived Intangible Assets [Line Items]
Period of notice for termination of the agreement	90 days	90 days
Amortization of deferred license fees [Abstract]
Up-front payment	$ 1,000,000
Expected life of agreement	3 years 3 months	3 years 3 months
Recognized revenue	$ 77,000
Maximum period to milestone payments become due	14 days	14 days
Uncured agreement period	60 days	60 days